5:15 PM
 | 
Jan 20, 2012
 |  BC Extra  |  Company News

Insmed up as FDA lifts Arikace hold in NTM

Insmed Inc. (NASDAQ:INSM) jumped $1.21 (32%) to $5.01 on Friday after FDA lifted a clinical hold on development of Arikace in patients with non-tuberculosis mycobacteria (NTM) lung infection, but maintained a hold in cystic fibrosis patients...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >